The care of patients with hematologic and oncologic conditions is the focus of the sixth book in the Pharmacotherapy Self-Assessment Program, seventh edition (PSAP-VII). Oncology provides evidence-based information on a wide range of problems seen in this patient population.

Oncology, which will be released April 15, has three learning modules offering a total of 16.5 continuing pharmacy education credits. The book describes new indications and new drugs used in the medical management of patients with cancer and blood disorders. The first module has chapters on supportive care of the patient with cancer; screening for common cancers and prevention of cancer, including pharmacologic treatment of patients who are at high risk; and nonmalignant hematology, including primary immune thrombocytopenia and paroxysmal nocturnal hemoglobinuria. The second module has updates on the treatment of pancreatic cancer and neuroendocrine tumors, hepatic cancer and hepatic metastases, and head and neck cancer. The third module contains chapters on gynecologic malignancies; non-Hodgkin lymphomas; and applications of bone marrow transplantation in multiple myeloma, germ cell tumors, and hematologic malignancies.

Oncology is designed to assist pharmacists who want to:

• Design appropriate supportive care regimens for patients with gastrointestinal effects, hypercalcemia, and osteoporosis associated with cancer and its treatment, and assess and improve drug adherence in patients with cancer.
• Plan appropriate screening for common cancers in patients who are at normal or high risk, and recommend chemopreventive therapy for patients who are at risk of developing breast, colon, prostate, and cervical cancer.
• Devise treatment plans for patients with primary immune thrombocytopenia and paroxysmal nocturnal hemoglobinuria, incorporating drugs that have been marketed recently, and assess the impact of treatment on quality of life.
• Design appropriate treatment regimens for patients with pancreatic cancer and neuroendocrine tumors, considering patient characteristics, impact of treatment on survival, and adverse effects of treatment.
• Evaluate the efficacy and toxicity of surgery, transplantation, locoregional therapy, and systemic therapy for patients with primary hepatic carcinoma and hepatic metastases from colon cancer.
• Develop a treatment plan for a patient with head and neck cancer, including local treatment, chemotherapy, targeted therapy, and supportive interventions.
• Assess the risk of gynecologic malignancies, discuss prevention options, and design treatment plans for patients with newly diagnosed or recurrent cancers of the endometrium, cervix, and ovary.
• Assess the prognosis of and develop a treatment plan for an indolent, aggressive, or highly aggressive non-Hodgkin lymphoma, including management of adverse effects.
• Discuss the role of hematopoietic cell transplantation in patients with multiple myeloma, non-Hodgkin and Hodgkin lymphomas, acute leukemias, chronic myeloid leukemia, aplastic anemia, and germ cell tumors and develop supportive care plans for patients with these conditions.

All PSAP-VII books are available in both print and online formats and as either single books or the full series (11 books). Other books in the series are Cardiology; Critical and Urgent Care; Women’s and Men’s Health; Pediatrics; Chronic Illnesses; Geriatrics; Science and Practice of Pharmacotherapy; Infectious Diseases; Neurology/Psychiatry; and Gastroenterology/Nutrition.

Each PSAP-VII book offers the most up-to-date and comprehensive information available on recent drug therapy advances and will expand your knowledge in the therapeutic area covered. For specific information on the release date, continuing pharmacy education credits, and program numbers for each book, or to place your online order, visit www.accp.com/bookstore/psap7.aspx. Books are priced as follows; shipping and handling charges apply to print books only.

ACCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The Board of Pharmacy Specialties (BPS) has approved PSAP-VII for use in Board Certified Pharmacotherapy Specialist (BCPS) recertification.